Wholesaler forecasts multi-year growth for GLP-1s

Glucagon-like peptide-1 medications are already delivering significant growth for wholesalers, but the best is yet to come, Symbion’s chief executive says  Uptake of glucagon-like peptide-1 (GLP-1) products in Australia is on track for significant growth over the coming years, with an oral formulation likely to fuel further demand, Symbion chief executive, Brett Barons, believes.   Barons told an investor presentation